Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,343
  • Shares Outstanding, K 27,096
  • Annual Sales, $ 1,520 K
  • Annual Income, $ -73,960 K
  • 60-Month Beta 2.61
  • Price/Sales 127.71
  • Price/Cash Flow N/A
  • Price/Book 2.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.44
  • Number of Estimates 5
  • High Estimate -0.39
  • Low Estimate -0.55
  • Prior Year -0.74
  • Growth Rate Est. (year over year) +40.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.38 +14.73%
on 04/23/19
8.03 -8.84%
on 05/08/19
+0.97 (+15.28%)
since 04/22/19
3-Month
4.52 +61.95%
on 03/22/19
8.03 -8.84%
on 05/08/19
+1.01 (+16.01%)
since 02/22/19
52-Week
3.39 +115.93%
on 12/26/18
9.52 -23.11%
on 05/25/18
-1.37 (-15.77%)
since 05/22/18

Most Recent Stories

More News
Syndax to Present at the UBS Global Healthcare Conference

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs...

SNDX : 7.32 (unch)
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 7.32 (unch)
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter...

SNDX : 7.32 (unch)
Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it...

SNDX : 7.32 (unch)
Research Report Identifies Chimerix, Evolent Health, ABIOMED, Syndax Pharmaceuticals, Independence Realty Trust, and Selecta Biosciences with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Chimerix, Inc. (NASDAQ:CMRX),...

EVH : 14.50 (-0.28%)
ABMD : 265.48 (+1.97%)
SNDX : 7.32 (unch)
IRT : 10.98 (+0.46%)
SELB : 2.46 (+3.80%)
CMRX : 3.49 (-0.29%)
Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation...

MRK : 80.98 (+1.86%)
SNDX : 7.32 (unch)
Syndax Announces $26.2 Million Offering of Common Stock and Warrants

Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered...

SNDX : 7.32 (unch)
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial...

SNDX : 7.32 (unch)
Syndax to Present at the Cowen 39th Annual Health Care Conference

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs...

SNDX : 7.32 (unch)
Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral...

SNDX : 7.32 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade SNDX with:

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

2nd Resistance Point 7.78
1st Resistance Point 7.55
Last Price 7.32
1st Support Level 7.15
2nd Support Level 6.98

See More

52-Week High 9.52
Last Price 7.32
Fibonacci 61.8% 7.18
Fibonacci 50% 6.46
Fibonacci 38.2% 5.73
52-Week Low 3.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar